she just keeps chugging along the pace has picked up more recently tho'nightspore could easily be right - prices can be factored in to expected resultsi think irm may have taken the market a little by surprise, hence the steep rise - not so rvr
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
